|
|
|
|
Antidepressant May Be Useful for Stroke Patients
Not a member yet?HealthandAge member? please Or By: June Chen, MD Escitalopram is a selective serotonin reuptake inhibitor typically used to treat depression? Now, it seems that escitalopram may be useful in stroke, as well. According to a...
|
|
|
Antidepressant May Aid Post-Stroke Cognitive Recovery
TUESDAY, Feb.2 (HealthDay News) -- Stroke patients who receive the antidepressant escitalopram within three months of their stroke show improvement in cognitive functioning as compared to those receiving either placebo or Problem Solving Therapy,...
|
|
|
Antidepressant May Result in Improved Cognitive Function After Stroke
CHICAGO, Feb.1, 2010Patients who received the antidepressant escitalopram following a stroke appeared to recover more of their thinking, learning and memory skills than those taking placebo or participating in problem-solving therapy, according to a...
|
|
|
Escitalopram and Enhancement of Cognitive Recovery Following Stroke
_ Escitalopram and Enhancement of Cognitive Recovery Following Stroke.
|
|
|
Antidepressant may Help Stroke Victims With Improved Cognitive Function
Victims of stroke who received the antidepressant escitalopram showed improvement in their thinking, learning and memory skills than those taking placebo or participating in problem-solving therapy, according to a report in the February issue of Archives...
|
|
|
Escitalopram May Improve Cognitive Function After Stroke
-- Patients who received the antidepressant escitalopram following a stroke appear to recover more of their thinking, learning, and memory skills than those taking placebo or participating in problem-solving therapy, according to a study published in the...
|
|
|
Escitalopram improves memory after stroke
NEW YORK (Reuters Health) - Depressed or not, patients treated early after a stroke with the antidepressant escitalopram do better over the longer term at cognitive function tests and activities of daily living, a small, single-center trial suggests.
|
|
|
Evidence suggests antidepressants may improve post-stroke recovery
Patients who received the antidepressant escitalopram following a stroke appeared to recover more of their thinking, learning and memory skills than those taking placebo or participating in problem-solving therapy, according to a report in the February...
|
|
|
Antidepressant May Result in Improved Cognitive Function After Stroke
Newswise Patients who received the antidepressant escitalopram following a stroke appeared to recover more of their thinking, learning and memory skills than those taking placebo or participating in problem-solving therapy, according to a report in the...
|
|
|
Antidepressants After Stroke May Boost Mental Ability
MONDAY, Feb.1 (HealthDay News) -- Taking antidepressants after a stroke may help repair the damaged brain and improve mental functioning, a new study suggests. Little has been shown to help the brain restore cognitive abilities, such as thinking, learning...
|
|
|
Antidepressants May Help Stroke Patients Recover Mental Skills
1 (Bloomberg) -- Forest Laboratories Inc.s antidepressant Lexapro may help stroke patients recover some of their mental skills, a study said.Patients who took Lexapro recovered more of their visual and verbal memory after 12 months of treatment than those...
|
|
|
Improving Depression and Enhancing Resilience in Family Dementia Caregivers: A Pilot Randomized Placebo-Controlled Trial of Escitalopram
Today in Geriatric Psych...Improving Depression and Enhancing Resilience in Family Dementia Caregivers: A Pilot Randomized Placebo-Controlled Trial of Escitalopram.
|
|
|
Psychiatric dermatology: Delusions of parasitosis
In most cases, delusions of parasitosis remain encapsulated and other mental functions are intact Success rate of study not high, in part due to patients' failure to return for follow-up Delusions of parasitosis resemble Morgellons disease Valhalla, N.Y.
|
|
|
Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Ch
(BUSINESS WIRE) Forest Laboratories, Inc.(NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.69 in the third quarter of fiscal 2010. Reported earnings per share included two one...
|
|
|
Answers to your questions about SSRIs
White C et al.Avoid prescribing a highly activating SSRI, such as fluoxetine, for patients for whom agitation is a presenting symptom. Consider citalopram and escitalopram, which have less potential for drug interactions and less complex dose...
|
|
|
Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Ch
NEW YORK(BUSINESS WIRE) Forest Laboratories, Inc.(NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.69 in the third quarter of fiscal 2010. Reported earnings per share included...
|
|
|
Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Ch
- Forest Laboratories, Inc.(NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.69 in the third quarter of fiscal 2010. Reported earnings per share included two one-time charges....
|
|
|
Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Ch
- Forest Laboratories, Inc.(NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.69 in the third quarter of fiscal 2010. Reported earnings per share included two one-time charges....
|
|
|
Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Charges Totaling $0.28 Per Share
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc.(NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.69 in the third quarter of fiscal 2010. Reported earnings per share...
|
|
|
Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Ch
Forest Laboratories, Inc.(NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.69 in the third quarter of fiscal 2010. Reported earnings per share included two one-time charges.
|
|
|
Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Charges Totaling $0.28 Per Share
NEW YORK-- (BUSINESS WIRE) -- Forest Laboratories, Inc.(NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.69 in the third quarter of fiscal 2010. Reported earnings per share...
|
|
|
Quality of sleep in escitalopram-treated female patients with panic disorder
Todder D et al.Patients with panic disorder rate their sleep worse than healthy controls. Quality of sleep in escitalopram-treated female patients with panic disorder.
|
|
|
Conclusion of Co-marketing Agreement for an Anti-Depressant, Escitalopram in Japan
Mochida Pharmaceutical Co., Ltd.Mitsubishi Tanabe Pharma Corporation (Tokyo, January 7, 2010) Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan, President: Naoyuki Mochida) and Mitsubishi Tanabe Pharma Corporation (Head office: Osaka, Japan,...
|
|
|
Mochida Pharmaceutical concludes agreement with Mitsubishi Tanabe Pharma for Escitalopram (MLD-55)
Mochida Pharmaceutical Co., Ltd.and Mitsubishi Tanabe Pharma Corporation (MTPC) have signed an agreement to co-market a selective serotonin reuptake inhibitor, Escitalopram, in Japan. Both the companies are based in Japan. Mochida Pharmaceutical...
|
|
|
EU probes Danish drug maker for generic drug delay
BRUSSELS-European Union regulators said Thursday that they suspect Danish drug maker Lundbeck may have delayed the launch of a cheaper, generic version of its antidepressant drug in Europe.The European Commission said it had opened a formal antitrust...
|
